ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer
Paul De Leyn, Didier Lardinois, Paul E. Van Schil et al. · European Journal of Cardio-Thoracic Surgery · 2007
Accurate preoperative staging and restaging of mediastinal lymph nodes in patients with non-small cell lung cancer (NSCLC) is of paramount importance. It will guide choices of treatment and determine prognosis and outcome. Over the last years, different techniques have become available. They vary in accuracy and procedure-related morbidity. The Council of the ESTS initiated a workshop on preoperative mediastinal lymph node staging. This resulted in guidelines for primary staging and restaging. For primary staging, mediastinoscopy remains the gold standard for the superior mediastinal lymph nodes. Invasive procedures can be omitted in patients with peripheral tumors and negative mediastinal positron emission tomography (PET) images. However, in case of central tumors, PET hilar N1 disease, low fluorodeoxyglucose uptake of the primary tumor and LNs > or = 16 mm on CT scan, invasive staging remains indicated. PET positive mediastinal findings should always be cyto-histologically confirmed. Transbronchial needle aspiration (TBNA), ultrasound-guided bronchoscopy with fine needle aspiration (EBUS-FNA) and endoscopic esophageal ultrasound-guided fine needle aspiration (EUS-FNA) are new techniques that provide cyto-histological diagnosis and are minimally invasive. Their specificity is high but the negative predictive value is low. Because of this, if they yield negative results, an invasive surgical technique is indicated. However, if fine needle aspiration is positive, this result may be valid as proof for N2 or N3 disease. For restaging, invasive techniques providing cyto-histological information are advisable despite the encouraging results supported with the use of PET/CT imaging. Both endoscopic techniques and surgical procedures are available. If they yield a positive result, non-surgical treatment is indicated in most patients.
Cited by 494 works. doi:10.1016/j.ejcts.2007.01.075 Open-access PDF
Authors
- Paul De Leyn
- Didier Lardinois
- Paul E. Van Schil
- Ramón Rami–Porta
- Bernward Passlick
- Marcin Zieliński
- David A. Waller
- Antoon Lerut
- Walter Weder
References
- Regional Lymph Node Classification for Lung Cancer Staging
- Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed Tomography
- Noninvasive Staging of Non-small Cell Lung Cancer*
- ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer☆
- Invasive Staging of Non-small Cell Lung Cancer*
- Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial
- Mediastinal Lymph Node Staging With FDG-PET Scan in Patients With Potentially Operable Non-small Cell Lung Cancer
- Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival
- Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309)
- Accuracy of transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer: a meta-analysis